FIELD: tumor immunotherapy.
SUBSTANCE: Fab fragment of an anti-VEGF antibody is provided. An isolated Fab fragment of an anti-VEGF antibody contains a heavy chain variable region containing a CDR1 region of the following SEQ ID NO: 27, CDR2 with the following SEQ ID NO: 28, CDR3 with the following SEQ ID NO: 29; and a light chain variable region comprising CDR1 region of the following SEQ ID NO: 24, CDR2 with the following SEQ ID NO: 25, CDR3 with the following SEQ ID NO: 26. Also the following is proposed: a conjugate containing an antibody Fab fragment and a therapeutic agent, a nucleic acid encoding an antibody Fab fragment, an expression vector, a host cell, a method of producing an antibody Fab fragment, a pharmaceutical composition and a combination, and a method of treating an angiogenesis-related eye disease. The Fab fragment of the antibody effectively blocks the activity of VEGF165.
EFFECT: inventions can be used to treat eye diseases characterized by choroidal neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).
25 cl, 10 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2019 |
|
RU2747735C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODIES AGAINST HtrA1 AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2750285C2 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2795973C1 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
